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with Reserpine or Phenothiazines
Drug-induced Parkinsonism in the rat - A model for biochemical investigation of the Parkinson-syndrome, U
By K. AbdelRaheem, Else Gründig, F. Salvenmoser, R. Schedl and /. Weiss
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Summary: Parkinsonism was induced in rats by using phenothiazines (Butyrylperazin and Thioproperazin),
(P-group), or reserpine, (R-group). [U-14C)D-glucose was administered when the symptoms of Parkinsonism
had become fully developed. Concentrations and radioactivities of different metabolites were studied in brain,
liver and blood serum.
1. Both types of treatments resulted in a decrease in the synthesis of amino acids from [14C]glucose in the brain.
The concentrations of amino acids and the glycogen remained uneffected. Phenothiazines enhanced the
conversion of lipids, while reserpine increased their concentration.
2. Reduced de novo synthesis of amino acids was recorded in the liver. Phenothiazines resulted in the storage of
glycogen and lipids; reserpine resulted in the storage of lipids and enhanced the conversion of glycogen.
3. Both treatments caused a fall in the amino acid concentration of the blood serum. A rise in the specific radio-
activity of blood amino acids was observed in the P^group, while a decrease in specific radioactivity was
observed in the R-group. A hyperglycemia was induced in the R-group with reduced specific radioactivity of
glucose in both P- and R-groups. A reduction in lipid concentration of blood serum was achieved with an
increased specific radioactivity in P-group and decreased radioactivity in R-group.
4. The changes in amino acids common to both treatments are also observed in human Parkinsonism.
Der Einbau von [i/-14C]D-G/wc0se inMetabolite inHirngewebe, Leber und Blut von Ratten, die mit Reserpin
oder mit Phenothiazinen vorbehandelt wurden
Drogeninduzierter Parkinsonismus der Ratte - ein Modell für biochemische Untersuchungen des Parkinson-
syndroms, 2. Mitteilung
Zusammenfassung: In Ratten wurde ein Parkinsonoid durch Behandlung mit Phenothiazinen (Butyiylperazin und
Thioproperäzüi).— P-Gnippe — oder mit Reserpin — R-Gruppe — induziert. Zum Zeitpunkt der vollen Entwicklung
des Parkinsohpids wurde [U*14C]£>-Gliicose verabreicht. Konzentrationen und Radioaktivität verschiedener Meta-
bolite wurden in Hirngewebe, Leber und Blutserum untersucht.
1. Beide Behandlungsformen verursachten eine Verminderung der Aminosäuresynthese aus [14C] Glucose im Him-
gewebe. Die Konzentration der Summe der Aminosäuren und des Glykogens blieben unverändert. Phenothiazine
bewirkten einen verstärkten Umsatz von Lipiden, während Reserpin deren Konzentration erhöhte.
2. In der Leber wurde eine Verminderung der Neusynthese von Aminosäuren gefunden. Außerdem bewirkten Pheno-
thiazine eine Speicherung von Glykogen und Lipiden, Reserpin hingegen eine Speicherung von Lipiden und eine
Umsätzerhöhung von Glykogen.
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3. Beide Behandlungsweisen verursachten eine Abnahme der Aminosäurekonzentration im Serum. Es wurde ein
Ansteigen der spezifischen Radioaktivität in der P-Gruppe und eine Abnahme in der R-Gruppe gemessen. In der
R-Gruppe trat eine Hyperglykämie auf, die spezifische Radioaktivität der Blutglucose war aber in beiden Gruppen
vermindert. Die Lipidkonzentration im Serum nahm ebenfalls in beiden Gruppen ab, begleitet von einem Anstieg
der spezifischen Radioaktivität in der P-Gruppe und von einer Abnahme in der R-Gruppe.
4. Veränderungen, die durch beide Behandlungsformen induziert wurden: Veränderung im Aminosäuregleichgewicht,
die derjenigen vergleichbar war, die beim menschlichen Parkinsonismus auftritt.
Introduction
Parkinson's disease as well as human drug induced Parkin-
sonism have been reported to exhibit comparable
changes in the spectrum of amino acids in cerebro-
spinal fluid (1). The recorded changes of free amino
acids in brains of rats were comparable to those of
human CSF, in those cases where the experimental
tratment lead to akinesis, rigor and tremor (2). An in-
crease in the concentrations of serine, threonine and
glycine and a decreased glutamic acid concentration
were observed in human CSF as well as in brains of
rats.
Treatment with reserpine has been shown to induce
Parkinsonism (6). The preparation of a model that
shows drug-induced Parkinsonian symptoms needs
very careful treatment, since the effect of the tested
drugs on metabolism depends strongly on various
parameters: dosage, temperature (3), mode of applica-
tion (4), duration of treatment (5). It has been reported
that a strong cataleptic state produced by pheno-
thiazines is not suitable as a model of Parkinsonism
(6).
In the present work, the changes induced in the
different metabolites in two parkinsonian models pro-
duced by treatment with reserpine or phenothiazines,
have been studied. The investigation of whether induced
changes in amino acids, important as they are, occur
exclusively in the central nervous system is also one of
the objectives of our present work.
Materials and Methods
Animals
Wistar rats (150-180 g) kept on a normal diet were used in the
present work. The room temperature was kept at 32° C, and the
animals showed no signs of hypothermia.
Induction of Parkinsonism · .
By Reserpine: Treatment lasted for 4 days. Animals were given
intraperitoneal injection of 0.3 mg/kg reserpine on the first
and the third day and 0.8 mg/kg on the second and the fourth
day..
By Phenothiazines: Treatment lasted for 10 days. 2 mg/day
butyrylperazin were mixed with bread, and care was exercised
to ensure total consumption. On the day 11 animals were
injected subcutaneously with 27 mg/kg thioproperazin.
Four hours after application of the last drug, 666 kBq
[U-*4C)/)-glucose (Radiochemical Center Amersham) were
injected intravenously. Twenty minutes later, the animals were
decapitated.
Preparation of blood, tissues and homogenates
After decapitation, blood was collected and allowed to coagul-
ate, centrifuged and serum was separated and kept in deep
freeze. Brain and liver were removed immediatly after
decapitation. The brain was dissected on a cooling plate
(obtained from the firm of Neumann, München) at -20 °C,
according to the method ofPopow et al (7). All tissues were
frozen in dry ice and processed on the same day. The brain was
dissected into the following parts:
Cortex region: Neopallium frontal and parietal parts; appr.
20% of the hippocampus.
Striatum region: Putamen; globus pallidus; caput nuclei
caudati; commissurai plate; fornix.
Thalamus region: Thalamus and hypothalamus; fornix; cauda;
nuclei caudati; pedunculi cerebri.
Cerebellum
The remains of the brain after dissection were used for the
analysis of glycogen and lipids. Samples of kidney, spleen,
heart, gonads, adipose tissue and muscles were prepared, too.
Liver and the 4 brain regions were homogenized in a 10-fold
volume of 50 g/1 trichloroacetic acid at 0 °C. Homogenates were
centrifuged. The sediment was washed twice with distilled
water, and washings and supernatants were pooled.
Blood serum was deproteinized by mixing 1 ml serum with
1 ml 0.6 mol/1 perchloric acid. The mixture was centrifuged
at 3000 rpm. The sediment was washed with 1 ml of the
perchloric acid. The wash and the supernatant were pooled
and brought to pH 7 by addition of KOH solution. The precipit-
ated salt was removed by centrifugation. The supernatant was
brought to a total volume of 3.5 ml.
Measurement of radioactivities
The total radioactivities of different serum and tissue extracts
were measured by mixing 0.5 ml of the extract with a Bray
system (Packard Scintillation counter).
Estimation of ninhydrin reactive compounds and
amino acids
An aliquot of each extract was used to measure the ninhydrin-
reactive compounds using the method of Moore & Stein (8).
Another aliquot was placed into ion exchange resin Dowex
50 X 4 at pH 2.0. Amino acids were eluted, dried and dissolved
in distilled water. Separate aliquots of the amino acid extract
were used for measurement of concentration (8), and for the
determination of radioactivity using the Bray scintillation
mixture.
Estimation of quantity and radioactivity of lipids
The remains of the brains and a sample of liver were weighed
and homogenized in a ten fold volume of 100 g/1 trichloroacetic
acid. Tissue and serum lipids were extracted by a chloroform/
methanol mixture (9). The organic phase was separated and
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evaporated to dryness under vacuum. Total lipids were
estimated gravimetrically. Lipids were then dissolved in the
Bray system for the estimation of the radioactivity.
Estimation of tissue glycogen and serum glucose
The glycogen content of brain was estimated in the remaining
defatted brain, together with the aqueous trichloroacetic acid
extract, after lipid extraction. Liver glycogen was estimated
on a fresh tissue sample by homogenisation in a ten fold
volume of 100 g/1 trichloroacetic acid.
Both brain and liver extracts were treated with 600 g/l KOH.
Precipitated glycogen was washed with absolute ethanol (A.R.).
Glycogen was hydrolyzed with 0.75 mol/1 HC1 in a boiling
water bath. Aliquots were used to measure the glucose
content enzymatically using test packs (Calbiochem, Los
Angeles). Serum glucose was estimated in deproteinized
filtrate using the same method.
Measurements of the radioactivity were undertaken by mixing
tissue and serum extracts with twice the volume of 2,4-
diphenyl-hydrazine 10 g/l in HC1 (10). the products of the
reaction were extracted 3 times with a 10-fold volume of
ethyl acetate at 0 °C. The extract was evaporated to dryness
and radioactivity was measured, using the Bray scintillation
system.
Results
In the present work, the incorporation of 14C into the
different metabolites has been studied in rats pretreated
with phenothiazines or reserpine. The distribution of
radioactivity in different organs was calculated. Taking
the brain total radioactivity as 1.0, the radioactivities
ranged from 0.04 in the gonads to 0.32 in the kidney.
The liver showed the highest radioactivity (0.95),
second to the brain.
The incorporation of radioactivity into amino acids,
glycogen and lipids was studied in the brains and livers
of rats treated with phenothiazines or reserpine.,-
Distribution of radioactivity
Brain
1. Brain amino acids: The uptake of radioactivity into
amino acids in the brain was studied in different brain
regions (tab. 1). All groups showed that most of the
radioactivity was, in fact, incorporated into amino acids.
Thus, the control animals showed an incorporation which
varied from 0.73 in the stratum to 0.99 in the cere-
bellum.
The treated groups showed reduced total radioactivity in
the amino acids. Compared with the controls, total radio-
activity in the amino acids in the thalamus was decreased
to 0.86 and to 0.75 in the cortex in the P-group. On the
other hand, in the R-group, the total radioactivity frac-
tion varied from 0.54 in cerebellum to 0.40 in the
stria turn.
The incorporation of radioactivity into amino acids of
brain regions of treated groups showed a reduction which
was more pronounced in the R-group than in the P-
group. Conversely, the relative radioactivity of amino
Tab. 1. Distribution of radioactivity in amino acids in brain regions of rats treated with phenothiazines or reserpine. Values are given
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Differences from control significant at * 0.05 > P > 0.01
** 0.01 > P > 0.001
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acids compared to the total homogenate, was increased
in the cortex and striatum of treated groups, while a
reduction was noted in the thalamus and cerebellum of
treated groups.
2. Brain glycogen and lipids: Calculating the average
radioactivity in the different brain regions and taking
it as 1.0, the glycogen showed 0.0002, while the lipid
showed 0.007 radioactivity (tab. 2). Of the treated
animals, those in P-group showed increased incorpora-
tion of radioactivity in glycogen and lipids. On the
other hand, a decreased incorporation was observed
in the R-group.
Liver
1. Liver amino acids: A comparatively low level of
radioactivity was incorporated in amino acids in the
control group. It increased in the P-group and showed
a slightly lower value in the R-group (tab. 2). The
amount of radioactivity incorporated into amino acids
was found to decrease on treatment both with pheno?
thiazines (0.83) or with reseipine (0.55).
2. Liver glycogen and lipids: The relative values of
radioactivity in glycogen and lipids in the controls
were found to be 0.00004 and 0.004 resp. Treatment
with reserpine or phenothiazines increased the incorpora-
tion of radioactivity into glycogen and lipids (R-group
showed no change in the lipids).
Concentrations and specific radioactivities
Brain
1. Brain amino acids: The amino acid concentration is
similar in all brain regions studied in control animals.
The specific radioactivity of amino acids can be arranged
according to: cortex > cerebellum > striatum > thalarnus
(tab. 3). Treatment with phenothiazines or reserpine
produced a rise in the quantity of amino acids in the
cortex, with a lowering of the specific radioactivity; this
behaviour was more pronounced in the R- than the
P-group. On the other hand, the thalamus, striatum and
cerebellum showed a fall in the amino acid concentration
and in the specific radioactivity (the striatum, in the
R-group only, showed a rise in amino acid concentra-
tion). The relation changes in the R-group were greater
than in the P-group.
2. Brain glycogen and lipids: Control animals showed
higher specific radioactivity for glycogen than for lipids.
Treated groups showed ä rise in the concentration and
in the specific radioactivity of the glycogen. No change
has been seen in specific radioactivity in the R-group.
A fall was observed in the lipid concentration in P-group,
while its specific radioactivity increased. In the reserpine
group, a rise in lipid concentration was observed, while
the specific radioactivity decreased, indicating enhanced
formation of lipids from non carbohydrate sources
(tab. 4).
Tab. 2. Uptake of radioactivity into different metabolits in brain and liver of rats treated with phenothiazines or reserpine. Values are









































3513 ±824 0.79* - 2042 ±880 0.46*
1.0 ± 0.17 0.0002 1.17 ± 0.33 1.17 0.0003 1.0 ± 0.17 0.00





333 ± 80 0.079 278 . ± 65 0.83**
Glycogen
0.17 ± 0.033 0.00004 0.83 ± 0.017 4.00**
Lipids
1.5 ± 6.67 0.0035 75 ± 13.3 40.0**
. 3250 ±583 . 0.77**
0.11 183 ± 75 0.55
0.0003 0.33 ± 0.017 2.00*






* ... average of observations of different remaining brain regions (see methods)
Differences from control significant at * 0.05 > P > 0.01
** 0.01 > P > 0.001
J. Clin. Chem. Clin. Biochem. / Vol. 17, 1979 / No. 6
Raheem, Gr ndig, Salvenmoser, Schedl and Weiss: Incorporation of (U-14C]glucose 345
Tab. 3. Changes in the concentration and specific radioactivity of amino acids (AA) of different brain regions in rats treated with
phenothiazines or reserpine.
Values are given as χ ± s. η = 6 (each group)
Cortex region
Thalamus region










































































Differences from control significant at * 0.05 > P > 0.01
** 0.01 > P > 0.001
Tab. 4. Incorporation of radioactivity into glycogen (G) and lipids (L) in brains of rats treated with phenothiazines or reserpine.























































Difference from control significant at * 0.05 > P > 0.01
** 0.01 > P > 0.001
Liver
Highest specific radioactivity was shown by the amino
acids, followed by glycogen, then lipids (tab. 5). The
P-group showed a rise in amino acid concentration
(1.95) and a fall in its specific radioactivity (0.43). This
may indicate enhanced formation of amino acids from
non-carbohydrate sources, and depressed incorporation
of [14C]glucpse. On the other hand, the R-group showed
a fall in arnino acid concentration (0.74) and a fall in
its specific radioactivity (0.74), indicating that the drug
depressed amino acid synthesis from injected 14C.
The P-group showed a rise in the concentration and
specific activity of glyeogen, indicating enhanced glyco-
gen synthesis from injected 14C. Conversely, R-group
animals showed a fall in the level of glycogen and a rise
in its specific activity. This may indicate increased
incorporation of 14C into liver glycogen from injected
glucose.
A rise was observed in the concentration and specific
radioactivity of lipids in both P- and R-groups. The effect
in P-group was greater than in R-group. This result may
indicate de novo synthesis of lipids from labelled glucose,
stimulated by phenothiazines and reserpine.
Blood serum
The results of analysis of blood serum are given in
table 6. The treatment with phenothiazines and reserpine
produced a fall in total amino acids, the decrease being
greater in the P-group. The specific radioactivity in-
creased in the P-group and decreased in the R-group,
the former indicating enhanced incorporation of radio-
activity into amino acids.
A state of hyperglycemia was observed, and this was
pronounced in the R-group. On the other hand, a
decreased specific radioactivity of blood glucose was
observed in both treated groups, being greater in the
J. Clin. Chem. Clin. Biochem. / Vol. 17,1979 / No. 6
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Tab. 5. Incorporation of radioactivity into the amino acids (AA), glycogen (G) and iipids (L) in the livers of rats treated with pheno-





































































Differences from control significant at * 0.05 > P > 0.01
** 0.01 > P > 0.001
Tab. 6. Concentration and specific radioactivity of amino acids (AA), glucose (glc) and Iipids (L) in the blood serum of rats treated





































































Differences from control significant at * 0.05 > Ρ > 0.01
** 0.01 > Ρ > 0.001
P-group. This indicates the mobilisation of non-
labelled glycogen, and there was, in fact, a lowering
of liver glycogen in the R-group. The fall in the specific
radioactivity of serum glucose may explain the increased
specific radioactivity incorporated into liver and brain
amino acids, and glycogen.
A fall in the concentration of serum Iipids was observed
in both P- and R-groups. A rise was observed in the
specific radioactivity of serum Iipids in the P-group,
while in the R-group they showed a decrease in specific
radioactivity.
Discussion
In Parkinson9 disease as well as in drug induced Parkin-
sonism in man. and animals, previous reports indicate
identical alterations of the amino acid spectrum both
in CSF or CNS (11). The present study reports the
results of the change occurring in the metabolism of
amino acids, carbohydrates and Iipids in two models
of drug induced Parkinsonism in the rat.
In the phenothiazine-treated animals, the specific radio-
activity of amino acids decreased in the brain, while
their concentration remained nearly unaffected. This
may be explained in the light of previous work (1,2),
in which a decrease observed in glutamic acid was
compensated by an augmentation of glycine, serine and
related amino acids. There is a correlation between
glucose utilisation and glutamic acid level in the CNS;
thus, the disturbance of glucose metabolism was
reported to produce a decrease in the glutamic acid
level in the CNS (12). The reported simultaneous
increase in serine and glycine (1,2) occurs only in
extrapyramidal syndromes (11).··
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Neuroleptics of the phenothiazine type are still studied
in connection with their effects onX-DOPA metabolism
(13-21). These drugs are postulated to provoke extra-
pyramidal disorders of movements by blocking the
dopaminergic receptors (22). It appears that this is not
the only cause of phenothiazine induced Parkinsonism.
It appears that the disturbances in the amino acids
glutamic acid and -aminobutyric acid may have addi-
tional influence on the balance of neurotransmitters (2).
It is found in the present work that the disturbances
recorded in the brain amino acids are quite different
from those in the liver. The present data show that liver
exhibited a marked increase in the amino acid concen-
tration but not in its specific radioactivity. This can be
attributed to the catabolism of protein or the bio-
synthesis of amino acids from non carbohydrate
substances.
Hyperglycemia was not recorded, but it has been
reported (4, 23) that hyperglycemia is produced by
chlorpromazin. In the present investigation, there
appeared to be an increase in the uptake of glucose,
as evidenced by the decrease in the specific radio-
activity of blood glucose. Moreover, tissues appear
to exhibit accelerated glucose catabolism under the
conditions of the present work. This view is supported
by the low incorporation of 14C into tissue glycogen.
The glycogen content in brain tissue was found to
be unchanged. Similar findings have been reported
following the application of chlorpromazin (24). The
concentration and the specific radioactivity of liver
glycogen was increased due to de novo synthesis.
Moreover, glycogenolysis may be reduced. Ras-
müssen (25) noted that chlorpromazin in vitro
impedes the epinephrine-controlled glycogen mobilisa-
tion by suppressed cAMP production.
Like the phenothiazines, reserpine can also produce
akinesis, tremor and -rigidity in men and in rats (26).
The monoamine storing vesicles become depleted in
brain and in peripheral tissues (27-31), which might
influence endocrine regulation (32). In our experi-
ments, specific radioactivity of amino acids decreased,
but the concentration remained unchanged. This is in
accordance with the effect of phenothiazines.
Reserpine as well as phenothiazines lowered the in-
corporation of 14C from [U-14C]glucose in the
brain and in the liver of rats, but the effect of reserpine
was less pronounced. In the present work the drug
caused a hyperglycemia, as reported earlier (33).
This could be due to a mobilisation of glycogen, since
the content of glycogen in liver and the specific radio-
activity of glucose in blood serum were both dimin-
ished. The increased specific radioactivity of liver
glycogen indicates an enhanced turnover. The present
findings seem to be in contrast to the observations of
other authors such us Balzer et al (34) and Albrecht
(35), who found an increased glycogen content in liver
after reserpine treatment. They interpreted their results
by an enhanced glycogenesis and simultaneous of
phosphorylase. This explanation is consistent with our
findings, because the glycogen content of the liver
depends on dosage and on the mode of application
of reserpine. Under different experimental conditions
phosphorylase is activated to different extents (31,
34,36).
In brain as well as in liver after reserpine application
we found an increase in lipids which are not synthesized
from [14C]glucose, whereas the treatment of rats by
phenothiazines, as performed in our laboratory, led to
an enhanced specific radioactivity of lipids.
The most important result of our investigation is the
fact that in the two models of Parkinsonism the only
alterations common to both are found in the amino
acid metabolism of the brain. Data concerning the
individual amino acids have been published previously
(38,39).
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